



COMMENTARY

Open Access

A new noninvasive technique for estimating hepatic triglyceride: will liver biopsy become redundant in diagnosing non-alcoholic fatty liver disease?

Bark Betzel¹ and Joost PH Drenth^{2*}

Abstract

Obesity and metabolic syndrome are healthcare problems that continue to rise in frequency worldwide. Both phenotypes are a strong predictor for development of liver steatosis in the context of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis. Ultrasound may detect steatosis, but its sensitivity is limited and liver biopsy is still considered to be the gold standard. Less invasive techniques that accurately quantify liver steatosis are warranted. Jiménez-Agüero and colleagues propose that multi-echo magnetic resonance imaging might be such a diagnostic tool. They validated multi-echo magnetic resonance imaging with measured hepatic triglyceride concentration. Their results show that this innovative technique measures the grade of steatosis in different clinical situations. Therefore, multi-echo magnetic resonance imaging might be considered for monitoring liver steatosis as an intermediate endpoint. Wide clinical applicability is limited though, as it does not allow differentiation between non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.

Keywords: Bariatric surgery, Hepatic fat concentration, Magnetic resonance imaging, Metabolic syndrome, Non-alcoholic fatty liver disease, Non-alcoholic steatohepatitis

Background

The incidence of obesity is increasing worldwide at an alarmingly fast pace, mainly because of a combination of cultural, social, and economic factors that affect lifestyle. Currently, one out of every three Americans is considered to be obese. Obesity is the main driver for the onset of metabolic syndrome, which is a group of metabolic abnormalities that share the cardiovascular risk factors hypertension, dyslipidemia, and hyperglycemia. Presence of metabolic syndrome including obesity is a strong predictor for hepatic steatosis, defined as lipid deposition in hepatocytes. Its phenotype ranges from non-alcohol fatty liver disease (NAFLD), to non-alcoholic steatohepatitis (NASH - fatty changes with inflammation and hepatocellular injury or fibrosis), to advanced fibrosis and cirrhosis.

Similar to obesity, NAFLD has reached epidemic proportions with a prevalence of 20% to 30% in western populations [1]. Because NAFLD constitutes a risk factor for NASH, it is to be expected that the prevalence of complicated liver disease in patients with obesity and metabolic syndrome will rise. As such, prevention of metabolic syndrome is a therapeutic target and lifestyle changes for patients at risk should be encouraged.

The question then arises, how to detect liver steatosis [2]? Ultrasound is by far the most frequently used modality to detect liver steatosis. Fatty infiltration of the liver produces a diffuse increase in echogenicity (a bright liver) and blurring of vascular margins and the diaphragm. Ultrasound, however, has some inherent disadvantages, such as a limited sensitivity to detect steatosis when less than 30% of hepatocytes contains fat, and its accuracy is compromised in patients who are obese. In addition, ultrasound cannot identify relevant liver disease in the context of NASH, such as steatohepatitis or fibrosis.

* Correspondence: joostphdrenth@cs.com

²Department of Gastroenterology and Hepatology, Radboud University Medical Center, PO Box 9101, Nijmegen 6500 HB, the Netherlands
Full list of author information is available at the end of the article

The gold standard for diagnosis of NAFLD and to differentiate it from NASH is liver biopsy. A liver biopsy should be considered in patients with liver steatosis on imaging who are at increased risk of steatohepatitis and advanced fibrosis, such as patients with competing etiologies for hepatic steatosis (for example, diabetes mellitus) and with co-existing liver disease. However, the invasive nature of liver biopsy with its risk for major complications, such as bleeding in approximately 1% of cases [3], precludes widespread use. Therefore, an accurate, easy to conduct, and less invasive technique is needed in diagnosing NAFLD [4]. Both computed tomography and magnetic resonance imaging (MRI) are more sensitive modalities for quantifying steatosis. However, none of these imaging techniques have sufficient sensitivity and specificity to stage the disease and cannot distinguish between NAFLD and NASH [5].

Jiménez-Agüero and colleagues [6] performed a rigorously designed and well-executed prospective study in 129 patients where hepatic lipid concentration was determined by three different methods. They performed histopathological examination of liver biopsies, measured hepatic triglyceride concentration from liver biopsy specimen (Folch method), and established liver fat fraction using multi-echo MRI. Multi-echo MRI was performed within 24 hours before collection of the biopsy, so no changes in hepatic fat content could occur due to the time interval. To improve diagnostic accuracy, they developed an equation that took into account the multi-echo MRI data, which was then validated in an additional cohort of 31 patients. After validation of the multi-echo MRI, this tool was tested to see if it could detect changes in liver fat content over time in obese patients. From the original cohort of 97 obese

patients, 86 underwent bariatric surgery while 11 were treated by partial liver resection. In total, 66 (56 and 11) patients received a second multi-echo MRI one year after surgery.

Applicability

Jiménez-Agüero and colleagues [6] validated a noninvasive tool (multi-echo MRI) with a biochemical quantification of hepatic triglyceride concentration. The key finding of the study is that accurate grading of steatosis with help of multi-echo MRI becomes possible. There are clear advantages of a noninvasive technique, especially when it comes to follow-up of patients with NAFLD undergoing treatment. In their hands, multi-echo MRI was able to predict the concentration of liver fat and demonstrated the improvement of steatosis after bariatric surgery. By contrast, in obese patients who underwent partial liver resection, hepatic steatosis remained unchanged. As such, multi-echo MRI allows monitoring of changes in hepatic fat content in different clinical situations.

Unfortunately, the applicability of this study in clinical practice stops there; it allows the differentiation between grades of steatosis. The technique does not differentiate between steatosis, steatohepatitis, and fibrosis. The ability to perform the latter is essential because the presence of steatohepatitis and fibrosis affects prognosis and influences disease management [7].

Bariatric surgery

The researchers took bariatric surgery as a model. Although patients eligible for bariatric surgery have a substantial risk for metabolic syndrome, it should be noticed that not all




Figure 1 Bariatric surgery leads to a decrease of liver steatosis, which can be detected by multi-echo magnetic resonance imaging.

these patients develop NAFLD: 11% of their obese patients did not have steatosis. The data of Jiménez-Agüero *et al.* [6] suggests that bariatric surgery reduces the liver fat fraction as measured by multi-echo MRI (Figure 1). Although bariatric surgery has superior effects on obesity and diabetes mellitus compared to conservative treatment [8], findings regarding beneficial effects on NAFLD and NASH are inconclusive [9]. Indeed, no randomized controlled trials have examined the effect of bariatric surgery on other components of metabolic syndrome, such as NAFLD or NASH. However, some anecdotal reports (such as the paper of Jiménez-Agüero *et al.* [6]) suggest regression and/or histological improvement of NAFLD or NASH after weight loss induced by bariatric surgery [10]. A rigorous clinical trial suggested that weight loss achieved through intensive lifestyle changes leads to improvement of histological signs of NASH [11].

Future perspectives

Multi-echo MRI is an attractive noninvasive technique to measure the grade of steatosis. However, as long as the grade of hepatic fat has no direct effect on liver disease, in contrast to NASH, multi-echo MRI at best measures an intermediate endpoint. Histopathological assessment of hepatitis and fibrosis, by means of a biopsy, remains the gold standard to differentiate between NAFLD and NASH. Therefore the use of multi-echo MRI is probably restricted to clinical research. On a different note, we encourage the development of new noninvasive techniques to grade steatosis because they can be of great value in patients with NASH. There, these techniques can play a role in monitoring the reduction of steatosis through lifestyle changes. In such cases, steatosis is a worthwhile intermediate endpoint that is associated with improved histological lesions that occur in NASH, such as hepatitis, hepatocellular ballooning and fibrosis.

Abbreviations

MRI: magnetic resonance imaging; NAFLD: non-alcoholic fatty liver disease; NASH: non-alcoholic steatohepatitis.

Competing interests

The authors declare that they have no competing interests.

Authors' information

JPHD is a hepatologist and Head of the Department of Gastroenterology and Hepatology at the Radboud University Nijmegen Medical Center, The Netherlands. His research interest covers (inherited) gastrointestinal diseases with a focus on the pathogenesis and treatment of polycystic liver disease. He aims to translate results from basic science into clinical reality. He has authored over 300 peer-reviewed articles, received a 2001 fellowship of the prestigious Dutch Academy of Art and Sciences, and is the recipient of the 2012 "Karel Lodewijk Verleijzen" prize of the Belgian Academy of Arts and Sciences. He has served at a number of committees of professional organizations at the national as well as the European level, most notably with the European Gastroenterology Federation (UEG). BB is a PhD student in bariatric surgery at the department of General Surgery at the Rijnstate Hospital, Arnhem, the Netherlands. His research focuses on endoscopic interventions in bariatrics.

Acknowledgement

The research that was needed to prepare this commentary received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Author details

¹Department of General Surgery, Rijnstate Hospital, Wagnerlaan 55, Arnhem 6815 AD, the Netherlands. ²Department of Gastroenterology and Hepatology, Radboud University Medical Center, PO Box 9101, Nijmegen 6500 HB, the Netherlands.

Received: 8 August 2014 Accepted: 12 August 2014

Published: 26 August 2014

References

1. Bellentani S, Scaglioni F, Marino M, Bedogni G: **Epidemiology of non-alcoholic fatty liver disease.** *Dig Dis* 2010, **28**:155–161.
2. Dyson JK, Anstee QM, McPherson S: **Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging.** *Frontline Gastroenterol* 2014, **5**:211–218.
3. Seeff LB, Everson GT, Morgan TR, Curto TM, Lee WM, Ghany MG, Shiffman ML, Fontana RJ, Di Bisceglie AM, Bonkovsky HL, Dienstag JL: **Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial.** *Clin Gastroenterol Hepatol* 2010, **8**:877–883.
4. Festi D, Schiumerini R, Marzi L, Di Biase AR, Mandolesi D, Montrone L, Scaioli E, Bonato G, Marchesini-Reggiani G, Colecchia A: **Review article: the diagnosis of non-alcoholic fatty liver disease – availability and accuracy of non-invasive methods.** *Aliment Pharmacol Therapeut* 2013, **37**:392–400.
5. Permutt Z, Le TA, Peterson MR, Seki E, Brenner DA, Sirlin C, Loomba R: **Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease - MRI accurately quantifies hepatic steatosis in NAFLD.** *Aliment Pharmacol Therapeut* 2012, **36**:22–29.
6. Raul Jiménez-Agüero JIE, Adolfo B, Luis B, Alustiza JM, Eli G, Elizabeth H, Lander G, Javier S, Perugorria MJ, Asensio JI, Santiago L, Maddi G, Mikel L, Portillo MP, Leixuri A, Banales JM: **Novel equation to determine the hepatic triglyceride concentration in humans by MRI: diagnosis and monitoring of NAFLD in obese patients before and after bariatric surgery.** *BMC Med* 2014, **12**.
7. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ: **The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.** *Hepatology* 2012, **55**:2005–2023.
8. Schauer PR, Bhatt DL, Kirwan JP, Wolksi K, Brethauer SA, Navaneethan SD, Aminian A, Pothier CE, Kim ES, Nissen SE, Kashyap SR: **Bariatric surgery versus intensive medical therapy for diabetes—3-year outcomes.** *N Engl J Med* 2014, **370**:2002–2013.
9. Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, Mendez-Sanchez N, Lizardi-Cervera J, Uribe M: **Bariatric surgery for non-alcoholic steatohepatitis in obese patients.** *Cochrane Database Syst Rev* 2010, **1**:CD007340.
10. Mathurin P, Hollebecque A, Arnalsteen L, Buob D, Leteurtre E, Caizzo R, Pigeyre M, Verkindt H, Dharancy S, Louvet A, Romon M, Pattou F: **Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease.** *Gastroenterology* 2009, **137**:532–540.
11. Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR, Fava JL, Wing RR: **Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis.** *Hepatology* 2010, **51**:121–129.

doi:10.1186/s12916-014-0152-z

Cite this article as: Betzel and Drenth: A new noninvasive technique for estimating hepatic triglyceride: will liver biopsy become redundant in diagnosing non-alcoholic fatty liver disease? *BMC Medicine* 2014 **12**:152.